Yeaseul Yoon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yeaseul Yoon has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Heon-Jeong Lee
Chronobiology Institute, Korea University, Seoul, Korea
4 shared publications - Ji Won Yeom
Department of Psychiatry, Korea University College of Medicine, Seoul, Republic of Korea
3 shared publications - Sojeong Kim
Department of Psychology, University of Oregon, Eugene, USA
3 shared publications - Chowon Park
Department of Psychiatry, Severance Hospital, Seoul, REPUBLIC OF KOREA
2 shared publications - Ha Young Lee
Department of Psychiatry and Center for Sleep and Chronobiology, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea
2 shared publications - Hyerin Gu
Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
2 shared publications
Latest Publications
- 1 May 2026
- Published by Hogrefe Publishing Group in Crisis
- Vol. 47 (3) , 129-139
Socioeconomic Inequalities in the Continuum of Suicidal Ideation
Background: Suicidal ideation changes over time. Few studies have examined socioeconomic inequalities in suicide ideation regarding interrelated indicators of incidence, persistence, and remission. Aim: We aimed to investigate how socioeconomic characteristics are related to the incidence, persistence, and remission of suicidal ideation in South Korea. Methods: We assessed the incidence of suicidal ideation at the 1-year follow-up among individuals without prior suicidal ideation and its persistence and remission at the 2-year follow-up. We conducted a multinomial logistic regression analysis to examine the association between SES and three indicators of the course of suicidal ideation. Results: Among 8,334 respondents, the 12-month incidence of suicidal ideation was 2.1%. Among these cases, 18.5% persisted, while 81.5% remitted. Low SES, particularly income, was strongly associated with the incidence, persistence, and remission of suicidal ideation. The socioeconomic association was strongest for persistent suicidal ideation (adjusted odds ratio [aOR]: 3.66; 95% confidence interval [CI]: 1.47–9.10), followed by incidence (aOR: 1.59; 95% CI: 1.10–2.29) and remission (aOR: 1.32; 95% CI: 0.88–1.97) of suicidal ideation. Limitations: We could not examine changes in these risk factors during the follow-up period. Conclusion: Adverse socioeconomic circumstances may precipitate the worsening in the course of suicidal ideation. Addressing the socioeconomic determinants of suicidal ideation should be prioritized.
- 1 May 2026
- Published by Hogrefe Publishing Group in Crisis
- Vol. 47 (3) , 129-139
Socioeconomic Inequalities in the Continuum of Suicidal Ideation
Background: Suicidal ideation changes over time. Few studies have examined socioeconomic inequalities in suicide ideation regarding interrelated indicators of incidence, persistence, and remission. Aim: We aimed to investigate how socioeconomic characteristics are related to the incidence, persistence, and remission of suicidal ideation in South Korea. Methods: We assessed the incidence of suicidal ideation at the 1-year follow-up among individuals without prior suicidal ideation and its persistence and remission at the 2-year follow-up. We conducted a multinomial logistic regression analysis to examine the association between SES and three indicators of the course of suicidal ideation. Results: Among 8,334 respondents, the 12-month incidence of suicidal ideation was 2.1%. Among these cases, 18.5% persisted, while 81.5% remitted. Low SES, particularly income, was strongly associated with the incidence, persistence, and remission of suicidal ideation. The socioeconomic association was strongest for persistent suicidal ideation (adjusted odds ratio [aOR]: 3.66; 95% confidence interval [CI]: 1.47–9.10), followed by incidence (aOR: 1.59; 95% CI: 1.10–2.29) and remission (aOR: 1.32; 95% CI: 0.88–1.97) of suicidal ideation. Limitations: We could not examine changes in these risk factors during the follow-up period. Conclusion: Adverse socioeconomic circumstances may precipitate the worsening in the course of suicidal ideation. Addressing the socioeconomic determinants of suicidal ideation should be prioritized.
- Open Access
- 25 August 2024
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 21 (8) , 918-924
Daily Self-Monitoring and Feedback of Circadian Rhythm Measures in Major Depression and Bipolar Disorder Using Wearable Devices and Smartphones–The Circadian Rhythm for Mood (CRM®) Trial Protocol: A Randomized Sham Controlled Double-Blind Trial
The circadian rhythm for mood (CRM) is a digital therapeutic, which aims to prevent mood episode and improve clinical course in patients with major mood disorders. Developed on the circadian rhythm hypothesis of mood disorder, CRM predicts the impending risk of mood episode with its built-in algorithm, utilizing wearable devices data and daily self-reports, and provides personalized feedback. In a pilot study of the CRM, the users experienced less frequent and shorter duration of mood episodes than the non-users. To investigate the efficacy of the upgraded CRM, a double-blind, randomized, sham-controlled, parallel-group trial is designed. Patients aged between 19 and 70, diagnosed with bipolar I disorder, bipolar II disorder, or major depressive disorder, in a euthymic state for more than two months, can participate. During this 12-month trial, participants are assessed for episode recurrence every three months, and the efficacy of the CRM as a potential digital therapeutic is evaluated. Trial registration: ClinicalTrials.gov Identifier: NCT05400785.
- 25 August 2024
- Published by Korean Neuropsychiatric Association in Psychiatry Investigation
- Vol. 21 (8) , 918-924
Open AccessDaily Self-Monitoring and Feedback of Circadian Rhythm Measures in Major Depression and Bipolar Disorder Using Wearable Devices and Smartphones–The Circadian Rhythm for Mood (CRM®) Trial Protocol: A Randomized Sham Controlled Double-Blind Trial
The circadian rhythm for mood (CRM) is a digital therapeutic, which aims to prevent mood episode and improve clinical course in patients with major mood disorders. Developed on the circadian rhythm hypothesis of mood disorder, CRM predicts the impending risk of mood episode with its built-in algorithm, utilizing wearable devices data and daily self-reports, and provides personalized feedback. In a pilot study of the CRM, the users experienced less frequent and shorter duration of mood episodes than the non-users. To investigate the efficacy of the upgraded CRM, a double-blind, randomized, sham-controlled, parallel-group trial is designed. Patients aged between 19 and 70, diagnosed with bipolar I disorder, bipolar II disorder, or major depressive disorder, in a euthymic state for more than two months, can participate. During this 12-month trial, participants are assessed for episode recurrence every three months, and the efficacy of the CRM as a potential digital therapeutic is evaluated. Trial registration: ClinicalTrials.gov Identifier: NCT05400785.
- Open Access
- 26 July 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e50555
Efficacy of Mobile App–Based Cognitive Behavioral Therapy for Insomnia: Multicenter, Single-Blind Randomized Clinical Trial
Background: Cognitive behavioral therapy for insomnia (CBTi) is the first-line therapy for chronic insomnia. Mobile app–based CBTi (MCBTi) can enhance the accessibility of CBTi treatment; however, few studies have evaluated the effectiveness of MCBTi using a multicenter, randomized controlled trial design. Objective: We aimed to assess the efficacy of Somzz, an MCBTi that provides real-time and tailored feedback to users, through comparison with an active comparator app. Methods: In our multicenter, single-blind randomized controlled trial study, participants were recruited from 3 university hospitals and randomized into a Somzz group and a sleep hygiene education (SHE) group at a 1:1 ratio. The intervention included 6 sessions for 6 weeks, with follow-up visits over a 4-month period. The Somzz group received audiovisual sleep education, guidance on relaxation therapy, and real-time feedback on sleep behavior. The primary outcome was the Insomnia Severity Index score, and secondary outcomes included sleep diary measures and mental health self-reports. We analyzed the outcomes based on the intention-to-treat principle. Results: A total of 98 participants were randomized into the Somzz (n=49, 50%) and SHE (n=49, 50%) groups. Insomnia Severity Index scores for the Somzz group were significantly lower at the postintervention time point (9.0 vs 12.8; t95=3.85; F2,95=22.76; ηp2=0.13; P<.001) and at the 3-month follow-up visit (11.3 vs 14.7; t68=2.61; F2,68=5.85; ηp2=0.03; P=.01) compared to those of the SHE group. The Somzz group maintained their treatment effect at the postintervention time point and follow-ups, with a moderate to large effect size (Cohen d=–0.62 to –1.35; P<.01 in all cases). Furthermore, the Somzz group showed better sleep efficiency (t95=–3.32; F2,91=69.87; ηp2=0.41; P=.001), wake after sleep onset (t95=2.55; F2,91=51.81; ηp2=0.36; P=.01), satisfaction (t95=–2.05; F2,91=26.63; ηp2=0.20; P=.04) related to sleep, and mental health outcomes, including depression (t95=2.11; F2,94=29.64; ηp2=0.21; P=.04) and quality of life (t95=–3.13; F2,94=54.20; ηp2=0.33; P=.002), compared to the SHE group after the intervention. The attrition rate in the Somzz group was 12% (6/49). Conclusions: Somzz outperformed SHE in improving insomnia, mental health, and quality of life. The MCBTi can be a highly accessible, time-efficient, and effective treatment option for chronic insomnia, with high compliance. Trial Registration: Clinical Research Information Service (CRiS) KCT0007292; https://cris.nih.go.kr/cris/search/detailSearch.do?seq=22214&search_page=L
- 26 July 2024
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 26, e50555
Open AccessEfficacy of Mobile App–Based Cognitive Behavioral Therapy for Insomnia: Multicenter, Single-Blind Randomized Clinical Trial
Background: Cognitive behavioral therapy for insomnia (CBTi) is the first-line therapy for chronic insomnia. Mobile app–based CBTi (MCBTi) can enhance the accessibility of CBTi treatment; however, few studies have evaluated the effectiveness of MCBTi using a multicenter, randomized controlled trial design. Objective: We aimed to assess the efficacy of Somzz, an MCBTi that provides real-time and tailored feedback to users, through comparison with an active comparator app. Methods: In our multicenter, single-blind randomized controlled trial study, participants were recruited from 3 university hospitals and randomized into a Somzz group and a sleep hygiene education (SHE) group at a 1:1 ratio. The intervention included 6 sessions for 6 weeks, with follow-up visits over a 4-month period. The Somzz group received audiovisual sleep education, guidance on relaxation therapy, and real-time feedback on sleep behavior. The primary outcome was the Insomnia Severity Index score, and secondary outcomes included sleep diary measures and mental health self-reports. We analyzed the outcomes based on the intention-to-treat principle. Results: A total of 98 participants were randomized into the Somzz (n=49, 50%) and SHE (n=49, 50%) groups. Insomnia Severity Index scores for the Somzz group were significantly lower at the postintervention time point (9.0 vs 12.8; t95=3.85; F2,95=22.76; ηp2=0.13; P<.001) and at the 3-month follow-up visit (11.3 vs 14.7; t68=2.61; F2,68=5.85; ηp2=0.03; P=.01) compared to those of the SHE group. The Somzz group maintained their treatment effect at the postintervention time point and follow-ups, with a moderate to large effect size (Cohen d=–0.62 to –1.35; P<.01 in all cases). Furthermore, the Somzz group showed better sleep efficiency (t95=–3.32; F2,91=69.87; ηp2=0.41; P=.001), wake after sleep onset (t95=2.55; F2,91=51.81; ηp2=0.36; P=.01), satisfaction (t95=–2.05; F2,91=26.63; ηp2=0.20; P=.04) related to sleep, and mental health outcomes, including depression (t95=2.11; F2,94=29.64; ηp2=0.21; P=.04) and quality of life (t95=–3.13; F2,94=54.20; ηp2=0.33; P=.002), compared to the SHE group after the intervention. The attrition rate in the Somzz group was 12% (6/49). Conclusions: Somzz outperformed SHE in improving insomnia, mental health, and quality of life. The MCBTi can be a highly accessible, time-efficient, and effective treatment option for chronic insomnia, with high compliance. Trial Registration: Clinical Research Information Service (CRiS) KCT0007292; https://cris.nih.go.kr/cris/search/detailSearch.do?seq=22214&search_page=L
- Open Access
- 6 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Efficacy of Mobile App–Based Cognitive Behavioral Therapy for Insomnia: Multicenter, Single-Blind Randomized Clinical Trial (Preprint)
BACKGROUND Cognitive behavioral therapy for insomnia (CBTi) is the first-line therapy for chronic insomnia. Mobile app–based CBTi (MCBTi) can enhance the accessibility of CBTi treatment; however, few studies have evaluated the effectiveness of MCBTi using a multicenter, randomized controlled trial design. OBJECTIVE We aimed to assess the efficacy of Somzz, an MCBTi that provides real-time and tailored feedback to users, through comparison with an active comparator app. METHODS In our multicenter, single-blind randomized controlled trial study, participants were recruited from 3 university hospitals and randomized into a Somzz group and a sleep hygiene education (SHE) group at a 1:1 ratio. The intervention included 6 sessions for 6 weeks, with follow-up visits over a 4-month period. The Somzz group received audiovisual sleep education, guidance on relaxation therapy, and real-time feedback on sleep behavior. The primary outcome was the Insomnia Severity Index score, and secondary outcomes included sleep diary measures and mental health self-reports. We analyzed the outcomes based on the intention-to-treat principle. RESULTS A total of 98 participants were randomized into the Somzz (n=49, 50%) and SHE (n=49, 50%) groups. Insomnia Severity Index scores for the Somzz group were significantly lower at the postintervention time point (9.0 vs 12.8; t95=3.85; F2,95=22.76; ηp2=0.13; P<.001) and at the 3-month follow-up visit (11.3 vs 14.7; t68=2.61; F2,68=5.85; ηp2=0.03; P=.01) compared to those of the SHE group. The Somzz group maintained their treatment effect at the postintervention time point and follow-ups, with a moderate to large effect size (Cohen d=–0.62 to –1.35; P<.01 in all cases). Furthermore, the Somzz group showed better sleep efficiency (t95=–3.32; F2,91=69.87; ηp2=0.41; P=.001), wake after sleep onset (t95=2.55; F2,91=51.81; ηp2=0.36; P=.01), satisfaction (t95=–2.05; F2,91=26.63; ηp2=0.20; P=.04) related to sleep, and mental health outcomes, including depression (t95=2.11; F2,94=29.64; ηp2=0.21; P=.04) and quality of life (t95=–3.13; F2,94=54.20; ηp2=0.33; P=.002), compared to the SHE group after the intervention. The attrition rate in the Somzz group was 12% (6/49). CONCLUSIONS Somzz outperformed SHE in improving insomnia, mental health, and quality of life. The MCBTi can be a highly accessible, time-efficient, and effective treatment option for chronic insomnia, with high compliance. CLINICALTRIAL Clinical Research Information Service (CRiS) KCT0007292; https://cris.nih.go.kr/cris/search/detailSearch.do?seq=22214&search_page=L
- 6 July 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEfficacy of Mobile App–Based Cognitive Behavioral Therapy for Insomnia: Multicenter, Single-Blind Randomized Clinical Trial (Preprint)
BACKGROUND Cognitive behavioral therapy for insomnia (CBTi) is the first-line therapy for chronic insomnia. Mobile app–based CBTi (MCBTi) can enhance the accessibility of CBTi treatment; however, few studies have evaluated the effectiveness of MCBTi using a multicenter, randomized controlled trial design. OBJECTIVE We aimed to assess the efficacy of Somzz, an MCBTi that provides real-time and tailored feedback to users, through comparison with an active comparator app. METHODS In our multicenter, single-blind randomized controlled trial study, participants were recruited from 3 university hospitals and randomized into a Somzz group and a sleep hygiene education (SHE) group at a 1:1 ratio. The intervention included 6 sessions for 6 weeks, with follow-up visits over a 4-month period. The Somzz group received audiovisual sleep education, guidance on relaxation therapy, and real-time feedback on sleep behavior. The primary outcome was the Insomnia Severity Index score, and secondary outcomes included sleep diary measures and mental health self-reports. We analyzed the outcomes based on the intention-to-treat principle. RESULTS A total of 98 participants were randomized into the Somzz (n=49, 50%) and SHE (n=49, 50%) groups. Insomnia Severity Index scores for the Somzz group were significantly lower at the postintervention time point (9.0 vs 12.8; t95=3.85; F2,95=22.76; ηp2=0.13; P<.001) and at the 3-month follow-up visit (11.3 vs 14.7; t68=2.61; F2,68=5.85; ηp2=0.03; P=.01) compared to those of the SHE group. The Somzz group maintained their treatment effect at the postintervention time point and follow-ups, with a moderate to large effect size (Cohen d=–0.62 to –1.35; P<.01 in all cases). Furthermore, the Somzz group showed better sleep efficiency (t95=–3.32; F2,91=69.87; ηp2=0.41; P=.001), wake after sleep onset (t95=2.55; F2,91=51.81; ηp2=0.36; P=.01), satisfaction (t95=–2.05; F2,91=26.63; ηp2=0.20; P=.04) related to sleep, and mental health outcomes, including depression (t95=2.11; F2,94=29.64; ηp2=0.21; P=.04) and quality of life (t95=–3.13; F2,94=54.20; ηp2=0.33; P=.002), compared to the SHE group after the intervention. The attrition rate in the Somzz group was 12% (6/49). CONCLUSIONS Somzz outperformed SHE in improving insomnia, mental health, and quality of life. The MCBTi can be a highly accessible, time-efficient, and effective treatment option for chronic insomnia, with high compliance. CLINICALTRIAL Clinical Research Information Service (CRiS) KCT0007292; https://cris.nih.go.kr/cris/search/detailSearch.do?seq=22214&search_page=L
- Open Access
- 30 June 2022
- Published by Chronobiology in Medicine in Chronobiology in Medicine
- Vol. 4 (2) , 86-90
Eveningness and Impulsivity in Euthymic Mood States Adversely Affect the Quality of Life of Major Depression and Bipolar Disorder Patients
Objective: Chronotype and impulsivity are important features to be examined in mood disorder patients; these characteristics precede mood disorder onset and persist between mood episodes. Moreover, quality of life is an important outcome in psychiatric patients. This study investigated the interaction between these features and its effect on mood disorder patient’s quality of life.Methods: Early-onset major depressive disorder (MDD), bipolar disorder I (BD I), and bipolar disorder II (BD II) patients were recruited. Excluding 18 patients who were missing data on main variables and 5 patients who were classified as severely ill, a total of 472 euthymic patients (MDD=167, BD I=133, BD II= 172) were assessed on their chronotype, trait impulsivity, and quality of life using self-reports.Results: Both impulsivity and eveningness were negatively associated with quality of life. Regression results showed that there was a significant interaction effect between eveningness and impulsivity on quality of life. This indicates that the higher the level of impulsivity in mood disorder patients, the negative effect of eveningness on quality of life increased.Conclusion: The current study suggests that examination of impulsive personality in relation to chronotype may be important in further understanding the effects of these features on mood disorder patients’ lives.
- 30 June 2022
- Published by Chronobiology in Medicine in Chronobiology in Medicine
- Vol. 4 (2) , 86-90
Open AccessEveningness and Impulsivity in Euthymic Mood States Adversely Affect the Quality of Life of Major Depression and Bipolar Disorder Patients
Objective: Chronotype and impulsivity are important features to be examined in mood disorder patients; these characteristics precede mood disorder onset and persist between mood episodes. Moreover, quality of life is an important outcome in psychiatric patients. This study investigated the interaction between these features and its effect on mood disorder patient’s quality of life.Methods: Early-onset major depressive disorder (MDD), bipolar disorder I (BD I), and bipolar disorder II (BD II) patients were recruited. Excluding 18 patients who were missing data on main variables and 5 patients who were classified as severely ill, a total of 472 euthymic patients (MDD=167, BD I=133, BD II= 172) were assessed on their chronotype, trait impulsivity, and quality of life using self-reports.Results: Both impulsivity and eveningness were negatively associated with quality of life. Regression results showed that there was a significant interaction effect between eveningness and impulsivity on quality of life. This indicates that the higher the level of impulsivity in mood disorder patients, the negative effect of eveningness on quality of life increased.Conclusion: The current study suggests that examination of impulsive personality in relation to chronotype may be important in further understanding the effects of these features on mood disorder patients’ lives.